EcoDrugPlus

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSSTUG00000040284
Gene Symbol: ENPP2
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSTUG00000021214
Gene Symbol: EGLN1
3 Cross references
202 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSTUG00000034168
Gene Symbol: EGLN1
1 Cross references
151 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSTUG00000023339
Gene Symbol: EGLN1
3 Cross references
197 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSTUG00000022611
Gene Symbol: EGLN1
3 Cross references
197 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSSTUG00000021301
Gene Symbol: EGLN3
3 Cross references
147 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSSTUG00000004808
Gene Symbol: EGLN3
3 Cross references
194 Possible Orthologues:

Ell-Associated Factor Eaf-Like

Ensembl ID : ENSSTUG00000036912
Gene Symbol: LOC115147481
2 Cross references
190 Possible Orthologues:

Ell-Associated Factor Eaf-Like

Ensembl ID : ENSSTUG00000026657
Gene Symbol: LOC115177744
2 Cross references
190 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSSTUG00000008875
Gene Symbol: EPAS1
3 Cross references
205 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSSTUG00000034798
Gene Symbol: LOC115152824
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSSTUG00000010675
Gene Symbol: EDNRB
1 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).